In the light of this report and the absence of any other currently approved treatment, we propose that sRAGE or other forms of RAGE blockade might fill a critical gap in this disorder as a potential single-agent or supplementary candidate for ALS treatment. The gene discussed is AGER; the disease is amyotrophic lateral sclerosis.